CHAIROS - Effect of early brief intensification by chemoimmunotherapy with FCR [fludaraine + cyclophosphamide + rituximab] followed by FR and Rituximab maintenance on clinical response in chemo-naive patients with B-CLL [B-cell chronic lymphocytic leukaemia].

Trial Profile

CHAIROS - Effect of early brief intensification by chemoimmunotherapy with FCR [fludaraine + cyclophosphamide + rituximab] followed by FR and Rituximab maintenance on clinical response in chemo-naive patients with B-CLL [B-cell chronic lymphocytic leukaemia].

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms CHAIROS
  • Sponsors Roche
  • Most Recent Events

    • 20 Dec 2013 New source identified and integrated (ClinicalTrials.gov, NCT02013817)
    • 20 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Oct 2009 Planned number of patients changed from 57 to 40 as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top